Draper touts new bioprocessing method as ‘next big advance in CAR T-cell treatment’
According to the not-for-profit research and development company, smarter cell therapy production will be the next big advance in CAR T-cell treatment.
When asked how the company’s new MTD device will bring this advance to fruition, Jenna Balestrini, a program manager of cell bioprocessing and biomedical solutions at Draper cited two primary advancements to the system:
“First, Draper’s device greatly reduces the amount of vector required to achieve high levels of transduction,” she told us. Viral vectors, the delivery vehicle of genomic materials into specific cells, can account for as much as 75% of a treatment’s cost, according to the company.
“Second, the device removes the expense of additional touch labor and reduces the potential for contamination associated with ‘open systems,’” Balestrini added.
The device is designed to connect to a customer’s T-cell separation and activation systems, to create a closed, modular, and scalable system, she explained.
“We believe this should reduce the cost of manufacturing the therapy by a factor of two to four, and bring the manufacturing of the therapy to the cancer center rather than an offsite location, and potentially even the patient bedside,” she added.
How does it work?
Draper’s microfluidic transduction device uses transmembrane fluid flow to concentrate and co-localize target cells with viral vectors, explained Ken Kotz, a senior member of the technical staff in Draper’s biomedical solutions group.
“This closed microfluidic system effectively increases the vector concentration in the vicinity of the cells resulting in greatly improved transduction efficiency in a matter of minutes,” he told us.
“Following transduction, cells are recovered from the device through controlled flow conditions leading to highly efficient recovery of intact, viable cells.”
Collaboration and licensing
David O'Dowd, associate director of biomedical solutions at Draper said the company’s vision is to collaborate with CAR-T therapy producers to customize the microfluidic transduction device.
To manufacture the device, O'Dowd said the company would partner with a medical device manufacturer, but could also produce the system itself.
“The key is that the therapeutic collaborator will decide who manufactures the device,” he said. “Draper is prepared to license the IP covering the device, on an exclusive or non-exclusive basis.”
